Patient-Reported Outcome Response and Safety Profile in Patients With Moderately to Severely Active Rheumatoid Arthritis Treated With Baricitinib 2-mg

被引：1
|
作者：
Sholter, Dalton [1 ]
Wu, Jianmin [2 ]
Jia, Bochao [2 ]
Zhang, Hong [3 ]
Griffing, Kirstin [2 ]
Quebe, Amanda [2 ]
Birt, Julie [2 ]
Reis, Paulo [2 ]
Liu, Huaxiang [4 ]
Bingham, Clifton [5 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] TechData Serv, Prussia, PA USA
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Johns Hopkins Arthrit Ctr, Baltimore, MD USA
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：1109 / 1110
页数：2
相关论文
共 50 条
  • [41] Janus kinase inhibitor baricitinib for rheumatoid arthritis: Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)
    Alten R.
    Nitschmann S.
    Der Internist, 2017, 58 (12): : 1341 - 1344
  • [42] Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
    Smolen, Josef S.
    Kremer, Joel M.
    Gaich, Carol L.
    DeLozier, Amy M.
    Schlichting, Douglas E.
    Xie, Li
    Stoykov, Ivaylo
    Rooney, Terence
    Bird, Paul
    Sanchez Burson, Juan Miguel
    Genovese, Mark C.
    Combe, Bernard
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (04) : 694 - 700
  • [43] Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
    Strand, Vibeke
    Buch, Maya
    Tundia, Namita
    Camp, Heidi S.
    Suboticki, Jessica
    Goldschmidt, Debbie
    Wells, Alvin F.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [44] Impact of 24-or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
    Strand, Vibeke
    Tundia, Namita
    Friedman, Alan
    Camp, Heidi
    Suboticki, Jessica
    Goldschmidt, Debbie
    Fernan, Catherine
    Bergman, Martin
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [45] EFFECTS OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO DMARDS
    Li, Z.
    An, Y.
    Li, G.
    Wang, L.
    Kwok, K.
    Wu, Q.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 285 - 286
  • [46] Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis
    Panes, Julian
    Su, Chinyu
    Marren, Amy
    Yu, Dahong
    Woodworth, Deborah A.
    Zhang, Haiying
    Healey, Paul J.
    GASTROENTEROLOGY, 2016, 150 (04) : S1003 - S1003
  • [47] Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study
    Navarro-Millan, Iris
    Zinski, Anne
    Shurbaji, Sally
    Johnson, Bernadette
    Fraenkel, Liana
    Willig, James
    Danila, Maria I.
    Yun, Huifeng
    Curtis, Jeffrey R.
    Safford, Monika M.
    ARTHRITIS CARE & RESEARCH, 2019, 71 (01) : 80 - 87
  • [48] Acceptability and Content Validity of Patient-Reported Outcome Measures Considered From the Perspective of Patients With Rheumatoid Arthritis
    Shaw, Yomei
    Zhang, Chen
    Bradley, Matthew
    Simon, Teresa A.
    Schumacher, Rebecca
    McDonald, David
    Michaud, Kaleb
    ARTHRITIS CARE & RESEARCH, 2021, 73 (04) : 510 - 519
  • [49] Improvement in fatigue with mirikizumab therapy is associated with improvements in patient-reported outcomes in patients with moderately to severely active Crohn's disease
    Reguiero, Miguel
    Fischer, Monika
    Rubin, David T.
    Hibi, Toshifumi
    Bossuyt, Peter
    Juillerat, Pascal
    Pollack, Paul
    Zhou, Xian
    Protic, Marijana
    Hunter, Theresa
    Chan, Lai Shan
    Carlier, Hilde
    Hindryckx, Pieter
    SWISS MEDICAL WEEKLY, 2023, 153 : 26S - 27S
  • [50] Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis A Bayesian network meta-analysis of randomized controlled trials
    Lee, Y. H.
    Bae, S. -C.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (04): : 335 - 342
12345